#cirrhosis

Three fatty liver disease candidates miss the mark for effectiveness or safety.

The 2019 Liver Meeting in Boston provided an array of important findings about the treatment and prevention of chronic liver diseases.

Currently, there are no pharmacological treatments for liver fibrosis related to non-alcoholic steatohepatitis.

A pooled analysis of numerous clinical trials and real-world studies reached this conclusion.

Primary biliary cholangitis (PBC) is a chronic liver disease resulting from the destruction of the bile ducts in the liver.

People treated with Viread, Vemlidy or Baraclude are less likely to develop this malignancy.

A new classification system may more accurately reflect liver-related death trends in the United States.

This is the first major study to assess an eight-week regimen in people with all genotypes of hep C and compensated cirrhosis.

A large Canadian study found that just 2% of such women developed more severe cirrhosis within one year of delivery.

We all know that the sooner one treats a disease the greater are the chances of a cure without sustaining permanent damage from the disease.

In the era of highly effective treatments for both viruses, HIV doesn’t speed the advancement of cirrhosis.

The indication for AbbVie’s regimen includes those with compensated cirrhosis.

South Korean researchers found no difference in the rates of liver cancer, liver transplant or death based on the treatment used.

If I was going to make it, there was some work do. We found out that the whole family was going to need healing with my liver cirrhosis.

Start off by understanding the symptoms and the source of liver damage. Then you can make yourself some promises.

Researchers have presented findings from the first large cohort of people followed over a lengthy period to assess this connection.